首页> 外文期刊>Egyptian Journal of Critical Care Medicine >Comparison of ECMO run between H1N1 acute respiratory failure vs. non H1N1 acute respiratory failure
【24h】

Comparison of ECMO run between H1N1 acute respiratory failure vs. non H1N1 acute respiratory failure

机译:H1N1急性呼吸衰竭与非H1N1急性呼吸衰竭之间ECMO运行的比较

获取原文
       

摘要

First case of adult ECMO was reported in 1971 however after that ECMO was hardly been used in adult till 2009. The real boost to ECMO in adult respiratory failure came after 2009 mainly contributed to successful Cesar trial & an outbreak of H1N1. There are ample of papers published on H1N1 & ECMO but hardly a few papers on ECMO in non H1N1 respiratory failure. However the incidence of acute respiratory failure secondary to other tropical infections like Malaria, dengue, leptospirosis, bacterial & viral pneumonia are much higher in India & Asian countries. ECMO is underutilized for these tropical infections especially in India mainly due to financial constraints but also because of lack of awareness & lack of published data to support. We thought of publishing our own data on role of ECMO and outcome in H1N1 & non H1N1 respiratory failure.MethodsIt is a Retrospective analysis of data collected of patients with acute respiratory failure managed on ECMO from January 2010 to November 2018.ResultsThe total 169 patients of respiratory failure were treated with ECMO during specified period. Out of this 169, 81 patients had H1N1 infection & remaining 88 were some other cause of respiratory failure all categorized under Non H1N1 group.There was not much difference in the survival in both the groups but ECMO runs remain significantly short (9.5 vs. 18.78?days) in non H1N1 group. Long run ECMO more than 30?days is seen in H1N1 with good survival (71.42%).ConclusionsECMO is equally effective in Non H1N1 & H1N1 respiratory failure with much shorter ECMO run in Non H1N1 respiratory failure. Survival with ECMO in tropical infections like Malaria, Dengue & Leptospirosis is more than 60%.
机译:成人ECMO的首例病例报道于1971年,但直到2009年才在成人中使用ECMO。2009年之后,成人呼吸衰竭对ECMO的真正推动作用主要是成功进行了Cesar试验和H1N1爆发。关于H1N1和ECMO的论文很多,但是关于非H1N1呼吸衰竭的ECMO的论文很少。然而,印度和亚洲国家继发于其他热带感染(如疟疾,登革热,钩端螺旋体病,细菌和病毒性肺炎)的急性呼吸衰竭的发生率要高得多。 ECMO对于这些热带感染的利用不足,尤其是在印度,主要是由于资金拮据,而且还因为缺乏认识和缺乏支持的公开数据。我们考虑发布自己的关于ECMO在H1N1和非H1N1呼吸衰竭中作用和结果的数据。方法是对从2010年1月至2018年11月在ECMO上管理的急性呼吸衰竭患者的数据进行的回顾性分析。结果在指定时期内用ECMO治疗呼吸衰竭。在这169例患者中,有81例H1N1感染,其余88例是呼吸衰竭的其他原因,均归为非H1N1组。两组的生存率差异不大,但ECMO的运行时间仍然很短(9.5比18.78) H1N1组除外?在H1N1中观察到超过30天的长期ECMO具有良好的生存率(71.42%)。结论E​​CMO在非H1N1和H1N1呼吸衰竭中同样有效,而在非H1N1呼吸衰竭中ECMO运行时间要短得多。 ECMO在诸如疟疾,登革热和钩端螺旋体病等热带感染中的存活率超过60%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号